Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
Sanofi (ENXTPA:SAN) secures European Commission approval to expand Dupixent use to children with chronic spontaneous urticaria. The company becomes the Canadian market authorization holder for ...
Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...
European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria: Paris Wednesday, April 15, 2026, 09:00 Hrs [IST] The Europ ...
Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...
Which children will develop seasonal allergic rhinitis is a complicated mix of environment and genetics, and data are adding ...
New data presented at the American Academy of Allergy, Asthma & Immunology annual meeting highlighted promising results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results